Spero Therapeutics, Inc. (SPRO)
$1.22+$0.01 (+0.83%) Today
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
https://www.sperotherapeutics.comSEC filings for SPRO on EDGAR
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 16 | 696,986 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
18 Form 4 filings on record, the earliest from Nov 12, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Debra Zack - Officer | Grant or award | Common Stock | 162,311 | $0.00 | - | |
| Debra Zack - Officer | Grant or award | Stock option (right to buy) | 324,675 | $0.00 | - | |
| Milind Deshpande | Grant or award | Common Stock | 10,000 | $0.00 | - | |
| Milind Deshpande | Grant or award | Stock Option (right to buy) | 20,000 | $0.00 | - | |
| Kathleen Tregoning | Grant or award | Common Stock | 10,000 | $0.00 | - | |
| Kathleen Tregoning | Grant or award | Stock Option (right to buy) | 20,000 | $0.00 | - | |
| Cynthia Smith | Grant or award | Common Stock | 10,000 | $0.00 | - | |
| Cynthia Smith | Grant or award | Stock Option (right to buy) | 20,000 | $0.00 | - | |
| Patrick V.J.J. Vink | Grant or award | Common Stock | 10,000 | $0.00 | - | |
| Patrick V.J.J. Vink | Grant or award | Stock Option (right to buy) | 20,000 | $0.00 | - | |
| Frank E. Thomas | Grant or award | Stock Option (right to buy) | 20,000 | $0.00 | - | |
| Frank E. Thomas | Grant or award | Common Stock | 10,000 | $0.00 | - | |
| Scott Thomas Jackson | Grant or award | Common Stock | 10,000 | $0.00 | - | |
| Scott Thomas Jackson | Grant or award | Stock Option (right to buy) | 20,000 | $0.00 | - | |
| John C. Pottage Jr. | Grant or award | Stock Option (right to buy) | 20,000 | $0.00 | - | |
| John C. Pottage Jr. | Grant or award | Common Stock | 10,000 | $0.00 | - | |
| Esther Rajavelu - Officer | Open-market sale | Common Stock | 25,240 | $2.51 | $63K | |
| Esther Rajavelu - Officer | Open-market sale | Common Stock | 37,101 | $2.36 | $88K | |
| Esther Rajavelu - Officer | Open-market sale | Common Stock | 50,816 | $2.36 | $120K | |
| Timothy Keutzer - Officer | Open-market sale | Common Stock | 18,652 | $2.36 | $44K | |
| Timothy Keutzer - Officer | Grant or award | Common Stock | 68,000 | $0.00 | - | |
| Timothy Keutzer - Officer | Open-market sale | Common Stock | 18,891 | $2.20 | $42K | |
| Timothy Keutzer - Officer | Open-market sale | Common Stock | 24,224 | $2.14 | $52K | |
| Timothy Keutzer - Officer | Open-market sale | Common Stock | 3,471 | $2.24 | $8K | |
| Timothy Keutzer - Officer | Grant or award | Stock Option (Right to Buy) | 137,000 | $0.00 | - | |
| Esther Rajavelu - Officer | Grant or award | Common Stock | 249,000 | $0.00 | - | |
| Esther Rajavelu - Officer | Open-market sale | Common Stock | 18,442 | $2.20 | $41K | |
| Esther Rajavelu - Officer | Grant or award | Stock Option (Right to Buy) | 498,000 | $0.00 | - | |
| Esther Rajavelu - Officer | Open-market sale | Common Stock | 40,270 | $2.37 | $95K | |
| Ankit Mahadevia | Open-market sale | Common Stock | 6,572 | $1.97 | $13K | |
| Timothy Keutzer - Officer | Open-market sale | Common Stock | 1,695 | $1.97 | $3K | |
| Frank E. Thomas | Grant or award | Common Stock | 20,000 | $0.00 | - | |
| Esther Rajavelu - Officer | Open-market sale | Common Stock | 23,351 | $1.31 | $31K | |
| Esther Rajavelu - Officer | Open-market sale | Common Stock | 17,245 | $1.30 | $22K |
Spero Therapeutics, Inc. (SPRO) had 8 insider filings in the last 90 days, with the most recent on 2026-08-06. The full record for SPRO runs to 18 Form 4 filings, the earliest from 2024-11-12. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of SPRO were filed in the last 90 days.
No insider sales of SPRO were filed in the last 90 days. 13 sales are on record for this company.
This page tracks SPRO Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add SPRO to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
